Submitted by Anonymous (not verified) on 20 November 2023 - 10:17
Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Date of authorisation: 22/09/2023, Revision: 1, Status: Authorised
Source: